Summit Therapeutics PLC experienced a significant uptick in its stock price following a strategic investment from AstraZeneca.
Summit Therapeutics PLC (NASDAQ:SMMT) saw its shares climb by 5.88% yesterday, closing at CA$16.39. This surge was primarily driven by AstraZeneca's announcement of a $2 billion investment in the company, aimed at accelerating the development of its lead cancer drug, ivonescimab.
Advertisement
Summit Therapeutics PLC
SMMT.US
SMMT.US
Summit Therapeutics PLC
WealthAwesomeMarket cap
$12.35B
52W high
$29.23
52W low
$12.07
1W change
-4.26%
Beta
-1.24
Analyst Price Targets
Based on 10 analysts covering SMMT · as of Sep 30, 2026
Wall Street analysts forecast SMMT stock price to rise 74.5% over the next 12 months.
Consensus
Strong Buy4.70 / 5.00
Avg. Target
C$28.60
+74.5% Upside
Previously C$28.64 on Sep 28, 2026
Current Price
C$16.39
Last close
Analyst Breakdown (10 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on SMMT's historical volatility
30-Day Vol
73.3%
Annualized
90-Day Vol
66.7%
Annualized
Trend (90d)
+12.0%
Annualized drift
90d Mean
C$17.11
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$16.62 | C$12.91 – C$21.41 |
| 60 trading days | C$16.86 | C$11.79 – C$24.12 |
| 90 trading days | C$17.11 | C$11.04 – C$26.51 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The substantial investment from AstraZeneca not only boosts Summit's financial standing but also validates its drug development strategy, potentially leading to significant advancements in cancer treatment.
$2 Billion Investment
AstraZeneca's investment represents a significant endorsement of Summit's pipeline, particularly the potential of ivonescimab in treating various cancers.
Bull case
The $2 billion investment from AstraZeneca gives Summit the capital it needs to enhance its clinical development programs, especially for ivonescimab. This partnership could lead to successful drug combinations that capture a larger market share in oncology.
Bear case
Even with this positive news, investors should stay cautious. The investment doesn’t remove the risks tied to drug development and regulatory approvals. Plus, the dilution of existing shares from the new equity could affect current shareholders.
Advertisement
AstraZeneca's Strategic Move
AstraZeneca's $2 billion investment in Summit Therapeutics is structured as a strategic equity deal, giving AstraZeneca rights to approximately 12% of Summit's outstanding common shares. This partnership aims to explore the combination of ivonescimab with AstraZeneca's existing oncology portfolio, potentially leading to innovative treatment options for gastrointestinal cancers.
Market Reactions and Future Prospects
The market responded positively to the news, with Summit's stock price reflecting investor optimism about the potential outcomes of the partnership. However, while the investment strengthens Summit's financial position, the clinical and regulatory risks associated with drug development remain a concern for investors.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
